A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2027-02-02

Summary

The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

• Phase: PHASE3

Details

• Lead Sponsor: GlaxoSmithKline
• Collaborator: iTeos Therapeutics
• Treatments: dostarlimab; pembrolizumab